{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:53:48Z","timestamp":1758981228297},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2002,2,21]],"date-time":"2002-02-21T00:00:00Z","timestamp":1014249600000},"content-version":"vor","delay-in-days":82,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two preparations of flunisolide, an inhaled corticosteroid, were compared in a parallel, multiple\u2010dose study of 31 healthy volunteers. The new flunisolide preparation substitutes hydrofluoroalkane (HFA) for chlorofluorocarbon (CFC) as a propellant and incorporates a spacer into its pressurized metered\u2010dose inhaler (pMDI). In this study, subjects were randomly assigned to receive flunisolide CFC 1000 \u00b5g bid; flunisolide HFA 170 \u00b5g bid; or flunisolide HFA 340 \u00b5g bid. Dosing was continued for 13.5 days. Plasma samples were analyzed after the first dose on day 1 and again after 13.5 days of treatment. No significant differences in day 1 dose\u2010adjusted peak plasma concentrations (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) were observed. Dose proportionality in <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and area under the concentration\u2013time curves (AUC) was observed for the flunisolide HFA 170 and 340 \u00b5g bid groups on days 1 and 14. Day 1 mean dose\u2010adjusted AUC was significantly greater in the flunisolide CFC 1000 \u00b5g bid group than in either flunisolide HFA group, indicating greater systemic availability of flunisolide CFC. Oral clearance and volume of distribution were significantly higher for flunisolide CFC than for flunisolide HFA. This may be due to greater oropharyngeal deposition by the flunisolide CFC formulation. Another indicator of greater flunisolide CFC oropharyngeal deposition was observed in <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and AUC<jats:sub>0\u2013tlast<\/jats:sub> values for 6\u03b2\u2010OH flunisolide, the first\u2010pass metabolite of flunisolide. The values of these pharmacokinetic parameters were significantly higher in the flunisolide CFC group than in the 340 \u00b5g bid flunisolide HFA group on days 1 and 14. However, this was not the case for cortisol values where flunisolide HFA accounted for less oropharyngeal deposition and more targeted delivery without adverse events. The study demonstrated that flunisolide HFA administered through a pMDI with built\u2010in spacer was safe and well tolerated in healthy volunteers. Copyright \u00a9 2001 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.274","type":"journal-article","created":{"date-parts":[[2002,9,11]],"date-time":"2002-09-11T02:05:12Z","timestamp":1031709912000},"page":"373-382","source":"Crossref","is-referenced-by-count":10,"title":["Flunisolide HFA vs flunisolide CFC: pharmacokinetic comparison in healthy volunteers"],"prefix":"10.1002","volume":"22","author":[{"given":"Arno","family":"Nolting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suryanarayana","family":"Sista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wattanaporn","family":"Abramowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,2,21]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/141.3.584"},{"key":"e_1_2_1_3_2","first-page":"A629","article-title":"Elevated peripheral airway resistance in nocturnal asthma is due to differing contributions from the airway and parenchyma","volume":"157","author":"Kraft M","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.1.9804053"},{"key":"e_1_2_1_5_2","unstructured":"The 1987 Montreal Protocol on Substances that Deplete the Ozone Layer: as adjusted and amended by the second Meeting of the Parties (London 27\u201329 June 1990) and by the fourth Meeting of the Parties (Copenhagen 23\u201325 November 1992) and further adjusted by the seventh Meeting of the Parties (Vienna 5\u20137 December 1995) and further adjusted and amended by the ninth Meeting of the Parties (Montreal 15\u201317 September 1997). Available athttp\/\/www.unep.org\/ozone\/mont_t.htm. Accessed January 16 2001."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(98)90211-6"},{"key":"e_1_2_1_7_2","article-title":"Flunisolide HFA is superior to placebo in improving lung function in asthma patients [abstract]","volume":"107","author":"Corren J","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_1_8_2","first-page":"405","volume-title":"Respiratory Drug Delivery VI","author":"Richards JC","year":"1998"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70016-3"},{"key":"e_1_2_1_10_2","unstructured":"National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma National Institutes of Health: Bethesda Md 1997. Publication No. 97\u2013405."},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.39.12.935"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1984.129.5.723"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.4.935"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.45.10.736"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.45.10.740"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.00493.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.9.941"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04263.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62517-3"},{"key":"e_1_2_1_20_2","first-page":"16","article-title":"Mechanism for the oxidative defluorination of flunisolide","volume":"218","author":"Teitelbaum TJ","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.54"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","unstructured":"CorrenJ NelsonH GreosL BenschG GoldsteinM WuJ WangS NewmanK.Effective control of asthma with hydrofluoroalkane (HFA) flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol2001(in press).","DOI":"10.1016\/S1081-1206(10)62922-5"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(99)90000-8"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1089\/jam.1996.9.Suppl_1.S-77","article-title":"In vivo measurements of aerosol dose and distribution: clinical relevance","volume":"9","author":"Laube BL","year":"1996","journal-title":"J Aerosol Med"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70043-6"},{"key":"e_1_2_1_26_2","first-page":"7","volume-title":"Asthma and the Small Airways","author":"Tashkin DP","year":"2000"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958004-00002"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.2500\/108854191778879601"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.274","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T16:09:38Z","timestamp":1700410178000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1002\/bdd.274"],"URL":"https:\/\/doi.org\/10.1002\/bdd.274","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}